Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatocellular Cancer
Studies from Fourth Military Medical University yield new data on hepatocellular cancer
August 25th, 2008
"Backgroud: Although the primitive haematopoietic and neuronal stem cell marker CD133 is known to be present in cancer stem cells (CSCs) in hepatocellular carcinoma (HCC), the postresection prognostic impact of CD133 in HCC patients remains limited. Sixty-three resected specimens were collected from HCC patients," scientists writing in the International Journal of Clinical Practice report. "The expression of CD133 protein was analysed by immunohistochemistry and the association of CD133 expression with clinicopathological characteristics, tumour recurrence and survival of the patients was evaluated. Immunohistochemical analysis of 63 HCC tissue specimens revealed...
Source: Stem Cell Week (2008-08-25)
|
